JP7035027B2 - Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン - Google Patents
Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン Download PDFInfo
- Publication number
- JP7035027B2 JP7035027B2 JP2019513958A JP2019513958A JP7035027B2 JP 7035027 B2 JP7035027 B2 JP 7035027B2 JP 2019513958 A JP2019513958 A JP 2019513958A JP 2019513958 A JP2019513958 A JP 2019513958A JP 7035027 B2 JP7035027 B2 JP 7035027B2
- Authority
- JP
- Japan
- Prior art keywords
- diazepine
- chlorophenyl
- ethynyl
- thieno
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C1=**=C2*1c([n]c(C#*)c1*)c1C(c1ccccc1)=*C2 Chemical compound *C1=**=C2*1c([n]c(C#*)c1*)c1C(c1ccccc1)=*C2 0.000 description 16
- VNOIIAHVJYKWCF-UHFFFAOYSA-N C#Cc1c[n](CCCC#Cc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)nn1 Chemical compound C#Cc1c[n](CCCC#Cc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)nn1 VNOIIAHVJYKWCF-UHFFFAOYSA-N 0.000 description 2
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- BXMPTABHXKPFHQ-VIFPVBQESA-N C[C@@H](c1nnc(C)[n]1-c([s]1)c2c(C)c1I)N=C2c(cc1)ccc1Cl Chemical compound C[C@@H](c1nnc(C)[n]1-c([s]1)c2c(C)c1I)N=C2c(cc1)ccc1Cl BXMPTABHXKPFHQ-VIFPVBQESA-N 0.000 description 2
- PGMQRYZQVRHFSE-UHFFFAOYSA-N Cc(c(C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]1-1)c-1[s]1)c1I Chemical compound Cc(c(C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]1-1)c-1[s]1)c1I PGMQRYZQVRHFSE-UHFFFAOYSA-N 0.000 description 2
- NKCRVSLFDGZZEX-UHFFFAOYSA-N OCCCC#Cc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound OCCCC#Cc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O NKCRVSLFDGZZEX-UHFFFAOYSA-N 0.000 description 2
- BJXDBXQZKWQSBV-UHFFFAOYSA-N C#Cc1c[nH]cn1 Chemical compound C#Cc1c[nH]cn1 BJXDBXQZKWQSBV-UHFFFAOYSA-N 0.000 description 1
- ZBQYZDNVOUABIJ-UHFFFAOYSA-N C#Cc1ncc(CCCCNc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)cc1 Chemical compound C#Cc1ncc(CCCCNc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)cc1 ZBQYZDNVOUABIJ-UHFFFAOYSA-N 0.000 description 1
- RFMGNXYYTBOQAV-UHFFFAOYSA-N C#Cc1ncc(COCCCCc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)cc1 Chemical compound C#Cc1ncc(COCCCCc2cccc3c2CN(C(CCC(N2)=O)C2=O)C3=O)cc1 RFMGNXYYTBOQAV-UHFFFAOYSA-N 0.000 description 1
- QPRHXGPAGFNADJ-KRXBUXKQSA-N C/C=C(\C#Cc1c[nH]cn1)/S Chemical compound C/C=C(\C#Cc1c[nH]cn1)/S QPRHXGPAGFNADJ-KRXBUXKQSA-N 0.000 description 1
- ONPIRZWOLVCPGQ-UHFFFAOYSA-N CC(C(C=C1)C2=NCc3nnc(C)[n]3-c3c2c(C)c(C#Cc2c[n](CCCC#Cc4cccc5c4CN(C(CCC(N4)=O)C4=O)C5=O)cn2)[s]3)C=C1Cl Chemical compound CC(C(C=C1)C2=NCc3nnc(C)[n]3-c3c2c(C)c(C#Cc2c[n](CCCC#Cc4cccc5c4CN(C(CCC(N4)=O)C4=O)C5=O)cn2)[s]3)C=C1Cl ONPIRZWOLVCPGQ-UHFFFAOYSA-N 0.000 description 1
- IAJMOILSUIJSMI-UHFFFAOYSA-N CS(OCCCC#Cc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)(=O)=O Chemical compound CS(OCCCC#Cc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O)(=O)=O IAJMOILSUIJSMI-UHFFFAOYSA-N 0.000 description 1
- ZAHJDBKKACFOQC-UHFFFAOYSA-N CS(OCCCCCc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)(=O)=O Chemical compound CS(OCCCCCc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)(=O)=O ZAHJDBKKACFOQC-UHFFFAOYSA-N 0.000 description 1
- YWNIISHGJPELBA-RUBXLXHKSA-N C[C@@H](c1nnc(C)[n]1-c1c2c(C)c(C#Cc3c[n](CCCCCc4cccc5c4CN(C(CCC(N4)=O)C4=O)C5=O)nc3)[s]1)N=C2c(cc1)ccc1Cl Chemical compound C[C@@H](c1nnc(C)[n]1-c1c2c(C)c(C#Cc3c[n](CCCCCc4cccc5c4CN(C(CCC(N4)=O)C4=O)C5=O)nc3)[s]1)N=C2c(cc1)ccc1Cl YWNIISHGJPELBA-RUBXLXHKSA-N 0.000 description 1
- MZJOVBREDPNNKF-PPVAYSNCSA-N C[C@@H](c1nnc(C)[n]1-c1c2c(C)c(C#Cc3cnc(CCCCNc4cccc5c4CN(C(CCC(N4)=O)C4=O)C5=O)cc3)[s]1)N=C2c(cc1)ccc1Cl Chemical compound C[C@@H](c1nnc(C)[n]1-c1c2c(C)c(C#Cc3cnc(CCCCNc4cccc5c4CN(C(CCC(N4)=O)C4=O)C5=O)cc3)[s]1)N=C2c(cc1)ccc1Cl MZJOVBREDPNNKF-PPVAYSNCSA-N 0.000 description 1
- FCOCTISPZQFCLQ-GWJDSUCGSA-N C[C@@H](c1nnc(C)[n]11)N=C(c(cc2)ccc2Cl)C(/C(/C)=C(\C)/C#Cc2c[n](CCCC#Cc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)nn2)=C1S Chemical compound C[C@@H](c1nnc(C)[n]11)N=C(c(cc2)ccc2Cl)C(/C(/C)=C(\C)/C#Cc2c[n](CCCC#Cc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)nn2)=C1S FCOCTISPZQFCLQ-GWJDSUCGSA-N 0.000 description 1
- PGYUBRMQDYIZFD-UHFFFAOYSA-N Cc1c(C#Cc2c[n](CCCC#C)cn2)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 Chemical compound Cc1c(C#Cc2c[n](CCCC#C)cn2)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 PGYUBRMQDYIZFD-UHFFFAOYSA-N 0.000 description 1
- FTOKUERYAJMQJF-UHFFFAOYSA-N Cc1c(C#Cc2c[n](CCCCCc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)nn2)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 Chemical compound Cc1c(C#Cc2c[n](CCCCCc3cccc4c3CN(C(CCC(N3)=O)C3=O)C4=O)nn2)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 FTOKUERYAJMQJF-UHFFFAOYSA-N 0.000 description 1
- GFUYCZDCAQCDGA-UHFFFAOYSA-N Cc1c(C#Cc2cnc[n]2CCCC#C)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 Chemical compound Cc1c(C#Cc2cnc[n]2CCCC#C)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 GFUYCZDCAQCDGA-UHFFFAOYSA-N 0.000 description 1
- PAZUSKGTBLWJAI-UHFFFAOYSA-N Cc1c[n](CCCCN)[n]c1 Chemical compound Cc1c[n](CCCCN)[n]c1 PAZUSKGTBLWJAI-UHFFFAOYSA-N 0.000 description 1
- MYGYXFCDNNRSJM-UHFFFAOYSA-N Cc1c[s]c(N)c1C(c1ccc(C)cc1)=O Chemical compound Cc1c[s]c(N)c1C(c1ccc(C)cc1)=O MYGYXFCDNNRSJM-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N Cc1ccc(C)cc1 Chemical compound Cc1ccc(C)cc1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- RHOOLJLEYYXKTK-UHFFFAOYSA-N Cc1cnc(C)nc1 Chemical compound Cc1cnc(C)nc1 RHOOLJLEYYXKTK-UHFFFAOYSA-N 0.000 description 1
- LHMZYMGVGMFPFJ-UHFFFAOYSA-N Cc1nnc(CNC)[nH]1 Chemical compound Cc1nnc(CNC)[nH]1 LHMZYMGVGMFPFJ-UHFFFAOYSA-N 0.000 description 1
- UNJJNIWGIYMKDN-UHFFFAOYSA-N NC(C=CC1)=C(CN2C(CCC(N3)=O)C3=O)C1C2=O Chemical compound NC(C=CC1)=C(CN2C(CCC(N3)=O)C3=O)C1C2=O UNJJNIWGIYMKDN-UHFFFAOYSA-N 0.000 description 1
- SCZFMUWTABGOGF-UHFFFAOYSA-N O=C(c1c(C2)c(Br)ccc1)N2C(CCC(N1)=O)C1=O Chemical compound O=C(c1c(C2)c(Br)ccc1)N2C(CCC(N1)=O)C1=O SCZFMUWTABGOGF-UHFFFAOYSA-N 0.000 description 1
- VROGWIJGMISOHP-UHFFFAOYSA-N OCCCCCc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound OCCCCCc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O VROGWIJGMISOHP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393923P | 2016-09-13 | 2016-09-13 | |
| US62/393,923 | 2016-09-13 | ||
| PCT/US2017/051286 WO2018052949A1 (en) | 2016-09-13 | 2017-09-13 | Fused 1,4-diazepines as bet protein degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526616A JP2019526616A (ja) | 2019-09-19 |
| JP2019526616A5 JP2019526616A5 (https=) | 2020-10-22 |
| JP7035027B2 true JP7035027B2 (ja) | 2022-03-14 |
Family
ID=60002003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513958A Expired - Fee Related JP7035027B2 (ja) | 2016-09-13 | 2017-09-13 | Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10975093B2 (https=) |
| EP (2) | EP3858837A1 (https=) |
| JP (1) | JP7035027B2 (https=) |
| CN (1) | CN110072866A (https=) |
| AU (1) | AU2017326175B2 (https=) |
| CA (1) | CA3036841A1 (https=) |
| ES (1) | ES2857743T3 (https=) |
| WO (1) | WO2018052949A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| WO2018144789A1 (en) * | 2017-02-03 | 2018-08-09 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN110357889B (zh) * | 2018-04-09 | 2022-03-15 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| TW202019946A (zh) | 2018-07-04 | 2020-06-01 | 日商田邊三菱製藥股份有限公司 | 具有ｂｅｔ蛋白質分解誘導作用的醯胺化合物及其作為醫藥的用途 |
| CN110407854B (zh) * | 2018-08-17 | 2020-09-15 | 北京加科思新药研发有限公司 | 新的四环化合物 |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| JP2022507267A (ja) * | 2018-11-13 | 2022-01-18 | バイオセリックス， インコーポレイテッド | 置換イソインドリノン |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| JP2023508891A (ja) * | 2019-12-17 | 2023-03-06 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解のための二機能性剤 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CA3173262A1 (en) | 2020-02-26 | 2021-09-02 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| WO2022156764A1 (zh) * | 2021-01-22 | 2022-07-28 | 泰比棣医药科技(石家庄)有限公司 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
| CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| CN115611881B (zh) * | 2021-07-13 | 2024-09-20 | 复旦大学 | 一种合成新型vhl配体4-f-vh032的方法 |
| WO2023074780A1 (ja) * | 2021-10-27 | 2023-05-04 | 国立大学法人愛媛大学 | 治療薬組成物 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN116585322B (zh) * | 2023-01-16 | 2023-10-13 | 中山大学中山眼科中心 | Bet蛋白降解剂在预防和治疗视网膜退行性改变相关疾病中的应用 |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| AU2024307234A1 (en) | 2023-06-30 | 2026-01-29 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025011624A1 (en) * | 2023-07-11 | 2025-01-16 | Etern Biopharma (Shanghai) Co., Ltd. | Bifunctional compounds for androgen receptor degradation and methods of use |
| WO2025096855A1 (en) | 2023-11-02 | 2025-05-08 | Kumquat Biosciences Inc. | Degraders and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060003995A1 (en) | 2004-06-30 | 2006-01-05 | Wisys Technology Foundation, Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| US20150291562A1 (en) | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63907A0 (en) | 1980-09-24 | 1981-12-31 | Cetus Corp | Diagnostic method and antibody probe for use therein |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
| DE69717160T2 (de) | 1996-09-13 | 2003-05-08 | Mitsubishi Pharma Corp., Osaka | Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen |
| FR2843126B1 (fr) | 2002-08-01 | 2006-01-27 | Cis Bio Int | "methode de determination d'une activite enzymatique endoglycosidase" |
| EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
| WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| DE102009051823A1 (de) | 2009-11-04 | 2011-05-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Einkristallines Schweißen von direktional verfestigten Werkstoffen |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| RS54645B1 (sr) | 2009-11-05 | 2016-08-31 | Glaxosmithkline Llc | Benzodiazepin kao inhibitor bromodomena |
| WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| WO2017176958A1 (en) * | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
-
2017
- 2017-09-13 CA CA3036841A patent/CA3036841A1/en active Pending
- 2017-09-13 US US16/332,544 patent/US10975093B2/en active Active
- 2017-09-13 CN CN201780069335.0A patent/CN110072866A/zh active Pending
- 2017-09-13 AU AU2017326175A patent/AU2017326175B2/en not_active Ceased
- 2017-09-13 EP EP20216642.7A patent/EP3858837A1/en not_active Withdrawn
- 2017-09-13 ES ES17778012T patent/ES2857743T3/es active Active
- 2017-09-13 EP EP17778012.9A patent/EP3512853B1/en not_active Not-in-force
- 2017-09-13 WO PCT/US2017/051286 patent/WO2018052949A1/en not_active Ceased
- 2017-09-13 JP JP2019513958A patent/JP7035027B2/ja not_active Expired - Fee Related
-
2021
- 2021-04-12 US US17/227,641 patent/US20220356192A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060003995A1 (en) | 2004-06-30 | 2006-01-05 | Wisys Technology Foundation, Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| US20150291562A1 (en) | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
Non-Patent Citations (3)
| Title |
|---|
| Armin, Walser; et al，Pentacyclic triazolodiazepines as PAF-antagonists，Journal of Heterocyclic Chemistry，1991年 月 日，28(4),，1121-1125 |
| Armin, Walser; et al，Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2，Journal of Medicinal Chemistry，1991年 月 日，34(4),，1440-1446 |
| Armin, Walser; et al，Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor，Journal of Medicinal Chemistry，1991年 月 日，34(3),，1209-1221 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3512853A1 (en) | 2019-07-24 |
| ES2857743T3 (es) | 2021-09-29 |
| AU2017326175A1 (en) | 2019-04-04 |
| US10975093B2 (en) | 2021-04-13 |
| AU2017326175B2 (en) | 2022-01-27 |
| EP3512853B1 (en) | 2020-12-23 |
| WO2018052949A1 (en) | 2018-03-22 |
| JP2019526616A (ja) | 2019-09-19 |
| US20190263827A1 (en) | 2019-08-29 |
| CA3036841A1 (en) | 2018-03-22 |
| CN110072866A (zh) | 2019-07-30 |
| US20220356192A1 (en) | 2022-11-10 |
| EP3858837A1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7035027B2 (ja) | Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン | |
| JP6961684B2 (ja) | Ｂｅｔタンパク質分解物質としての縮合１，４−オキサゼピン | |
| JP7072519B2 (ja) | Ｂｅｔタンパク質分解剤 | |
| JP6967522B2 (ja) | Ｂｅｔブロモドメイン阻害剤としての融合１，４−オキサゼピンおよび関連類似体 | |
| KR102387316B1 (ko) | Mdm2 단백질 분해제 | |
| CN110914265B (zh) | 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物 | |
| JP7094566B2 (ja) | Ａｌｋ阻害剤としてのアミノピリミジン類 | |
| JP2017511801A (ja) | ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体 | |
| CN110636843A (zh) | 作为共价多发性内分泌腺瘤蛋白抑制剂的哌啶 | |
| CN111936465A (zh) | 作为共价menin抑制剂的哌啶化合物 | |
| CN112119080B (zh) | 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物 | |
| US11267822B2 (en) | BET bromodomain protein degraders with cleavable linkers | |
| HK40041770A (en) | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200911 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200911 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210715 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211124 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220207 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220302 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7035027 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |